Litigation Details for Astellas Pharma Inc. v. Sandoz Inc. (D. Del. 2020)

Astellas Pharma Inc. v. Sandoz Inc. (D. Del. 2020)

Docket		Date Filed	2020-11-24
Court	District Court, D. Delaware	Date Terminated	2023-06-09
Cause	35:271 Patent Infringement	Assigned To	Joseph F. Bataillon
Jury Demand	Plaintiff	Referred To	Eleanor G. Tennyson
Parties	ASTELLAS PHARMA INC.
Patents	10,842,780; 11,707,451; 12,059,409; 12,097,189; 6,346,532; 6,562,375; 7,342,117; 7,982,049; 8,772,315; 8,835,474; 9,056,120; RE44,872
Attorneys	William A. Rakoczy
Firms	Young, Conaway, Stargatt & Taylor
Link to Docket	External link to docket

Details for Astellas Pharma Inc. v. Sandoz Inc. (D. Del. 2020)

Date Filed	Document No.	Description	Snippet	Link To Document
2020-11-24				External link to document
2020-11-24	1	Complaint	Book listed patent for Myrbetriq® Tablets, United States Patent No. 6,346,532 (“the ’532 Patent”) against… action for patent infringement of United States Patent No. 10,842,780 (“the ’780 Patent”), arising under…7,342,117 (“the ’117 Patent”), 7,982,049 (“the ’049 Patent”), 8,835,474 (“the ’474 Patent”) and RE44,872 (“the…the then-listed patents in the Orange Book for Myrbetriq® Tablets, United States Patent Nos. 7,342,117… the ’780 Patent because, inter alia, they concluded before the issuance of the ’780 Patent.	External link to document
2020-11-24	523	Redacted Document	accompanying Paragraph IV certification for U.S. Patent Nos. 7,342,117; 7,982,049; …accompanying Paragraph IV certification for U.S. Patent Nos. 7,342,117, 7,982,049, 8,835,474, and RE44,872 …, journal, patent, patent publication, certified file history of a patent or patent application, or… infringement of United States Patent No. 10,842,780 (“the ’780 Patent”) based on Sandoz’s September…infringement of United States Patent No. 10,842,780 (“the ’780 Patent”) based on Sandoz’s September	External link to document
2020-11-24	571	Order - Memorandum and Order	having been long known, e.g., U.S. Pat. No. 6,346,532; Astellas Pharma Inc. v. Actavis Elizabeth …MEMORANDUM AND ORDER, claims 5, 20, and 25 of U.S. Patent No. 10,842,780 are invalid. All pending motions…matter is before the Court for final decision on patent-infringement charges arising under the Hatch-Waxman…the heels of a previous suit involving different patents but the same Abbreviated New Drug Applications…contrasted by its inefficacy on a full one—U.S. Patent No. 10,842,780 claims the extended-release formulation	External link to document
2020-11-24	78	Counterclaim AND Answer to Complaint	Book listed patent for Myrbetriq® Tablets, United States Patent No. 6,346,532 (“the ‘532 Patent”) against…“Notification of Certification for U.S. Patent Nos. 6,346,532; 6,562,375; 7,342,117; 7,982,049; 8,835,474…Letter”) to the 6,346,532, 6,562,375, 7,342,117, 7,982,049, 8,835,474, and RE44,872 patent holder and the… action for patent infringement of United States Patent No. 10,842,780 (“the ‘780 Patent”), arising under…infringement of U.S. Patent No. 10,842,780 (“the 780 Patent”) arising under the United States patent laws and Title	External link to document

Litigation summary and analysis for Astellas Pharma Inc. v. Sandoz Inc., 1:20-cv-01589 (Paragraph IV patent challenge)

Last updated: June 7, 2026

Astellas Pharma Inc. v. Sandoz Inc., No. 1:20-cv-01589, is a federal Hatch-Waxman patent infringement case tied to a Sandoz generic entry challenged as infringing one or more Orange Book-listed Astellas patents for a brand product in the U.S. district court system. The case’s public docket filings control the factual record for claim construction, infringement contentions, and any settlement or non-infringement rulings.

What is Astellas Pharma Inc. v. Sandoz Inc. 1:20-cv-01589 about?

Short answer: Astellas alleges that Sandoz’s generic product infringes one or more Astellas Orange Book-listed patents via a Paragraph IV certification.

What court, parties, and docket identify the case

• Case caption: Astellas Pharma Inc. v. Sandoz Inc.
• Docket: 1:20-cv-01589
• Court: U.S. federal district court (district and judge not stated in the provided prompt)

What typically drives this case type

These Astellas v. Sandoz Hatch-Waxman matters generally center on:

• which Orange Book patents are asserted,
• whether the generic’s proposed label and manufacturing process fall within the asserted claims,
• whether Sandoz’s non-infringement and invalidity defenses defeat the asserted patent(s),
• and whether the parties reach a settlement that sets a launch date and/or design-around scope.

Which patents are asserted in 1:20-cv-01589?

Short answer: The asserted patent list is defined by the operative complaint and any later amended pleadings, which are not provided in the prompt.

How to read the patent footprint in this docket

In cases with this caption and number, the patent-specific details usually appear in:

• the complaint (asserted patent numbers and claim charts),
• PSLR/technical disclosures exchanged under district-court scheduling orders,
• and claim construction orders, if entered.

How claim scope typically matters

The strongest commercial signal for generic timing is:

• whether asserted claims are composition/formulation versus method-of-use,
• whether there are multiple layers of patents (drug substance, formulation, and use),
• and whether any asserted patents are thin (easy design-around) or broad (hard to avoid without changing the active ingredient or claim-specific formulation features).

What patents protect Astellas’s drug at issue in this case?

Short answer: Patents protecting the Astellas brand are those listed in the Orange Book for the relevant NDA/ANDA and identified as asserted in this specific docket.

Key deliverables for investors and licensing

For each asserted patent, the analysis typically covers:

• expiration date and patent term adjustments (PTA),
• remaining enforceability after any terminal disclaimers,
• priority date and claim breadth,
• prosecution history limits,
• and whether the patent is subject to reexamination or PTAB challenges.

When does exclusivity or patent protection for the Astellas product expire?

Short answer: Exclusivity and patent expiry are determined by (1) Orange Book listings for the NDA referenced by the ANDA, and (2) each asserted patent’s legal expiration, including PTA and patent-term adjustments.

Hatch-Waxman timing framework used in this docket class

• 30-month stay: commonly triggered by a Paragraph IV filing.
• First commercial availability: depends on whether the parties settle, the court issues a final merits ruling, or the stay lapses.
• Biosimilar risk analogue: not generally applicable to small-molecule Hatch-Waxman filings, but relevant if the underlying product is biologic (not confirmed in the prompt).

Is this case settled or still active?

Short answer: Settlement status and any final merits outcomes depend on docket entries (stipulations, dismissal with prejudice, settlement orders, or final judgments), which are not provided in the prompt.

What settlement usually contains

In Astellas v. Sandoz-style matters, settlement agreements typically govern:

• a launch date (carve-outs possible by strength and dosage form),
• design-around obligations for non-infringing structure/labeling,
• and sometimes mutual covenants tied to specific claims.

What is the claim construction and infringement/invalidity posture in 1:20-cv-01589?

Short answer: The infringement and invalidity posture is determined by the claim construction order and summary judgment record, neither of which appears in the prompt.

What to look for in court orders

For actionable analysis, the docket normally includes:

• Markman/claim construction dates and results,
• summary judgment rulings on validity/infringement,
• and Daubert decisions affecting expert admissibility.

How strong is Astellas’s patent estate in this litigation?

Short answer: Patent strength is not determinable from the prompt because it requires:

• asserted patent identification,
• claim construction outcomes,
• and the legal standards applied in the docket’s dispositive rulings.

Strength scoring model used by litigators and licensing teams

A practical strength evaluation for this case class usually weights:

• how many patents are asserted,
• whether the asserted claims survive construction,
• whether there is a dominant claim element that is easy to avoid,
• and whether invalidity arguments target well-established prior art.

What generic entry risks exist for Sandoz if Astellas wins or loses?

Short answer: Entry risk depends on the final judgment and any injunction scope; the prompt provides no final judgment or injunction record.

If Astellas wins

• Court typically issues an injunction barring sale of the accused ANDA product to the extent it practices the adjudicated infringing claims.
• Launch is delayed until design-around or patent expiry.

If Sandoz wins

• Invalidity or non-infringement can open the path to market at risk or immediately upon judgment effective dates.
• Potential appeal keeps market at uncertainty depending on stay motions.

How does this case compare with other Astellas v. generic litigation?

Short answer: No comparison is possible without the asserted patent(s), product identity, and docket outcome for 1:20-cv-01589.

What a comparison typically covers

• frequency of settlement versus litigated wins,
• rate of claim invalidation or narrow construction,
• and whether Astellas uses overlapping patent families across drugs.

What is the Orange Book status of the patents at issue?

Short answer: Orange Book status must be tied to the specific NDA/ANDA referenced in the complaint and the asserted patent numbers, which are not included in the prompt.

Orange Book fields that matter for enforcement and launch planning

• patent number
• expiration date (including PTA)
• dosage form and route
• exclusivity code (if relevant)
• and the “core” patent family controlling the 180-day exclusivity pathway (if any).

Key facts checklist for business decisions (docket-driven)

Because high-stakes analysis depends on docket specifics, this checklist is the operational map for what the case file determines:

1. Asserted patent numbers and asserted claims (from complaint and amendments).
2. ANDA applicant name and the accused generic NDA/ANDA entry details (from pleadings and disclosures).
3. Claim construction outcome for claim terms most central to infringement.
4. Validity theories asserted by Sandoz (anticipation, obviousness, written description, enablement, indefiniteness).
5. Dispositive rulings (summary judgment grants/denials).
6. Settlement terms (launch date, covenants, design-around).
7. Any injunction and its scope (claims, dosages, label carve-outs).
8. Appeal status (notice of appeal, appellate briefing schedule, stays).

Key Takeaways

• The case is a Hatch-Waxman-style patent infringement dispute under No. 1:20-cv-01589 between Astellas Pharma Inc. and Sandoz Inc.
• The actionable elements needed for litigation leverage and launch-risk planning are the asserted patent numbers, claim construction, final judgment/settlement, and Orange Book tie-in to the underlying NDA/ANDA.
• Those docket-controlled details are not present in the prompt, so a patent-specific or timeline-specific analysis cannot be stated from the information provided.

FAQs

1. What filings determine the asserted patents in 1:20-cv-01589?
2. How do claim construction outcomes drive infringement analysis for Astellas in Hatch-Waxman cases?
3. What does a Paragraph IV certification imply for the timing of Sandoz generic entry?
4. How do settlement terms in Astellas v. Sandoz cases typically allocate launch dates and design-around scope?
5. What Orange Book fields are most important for assessing enforceability and remaining patent life?

References

1. (No sources cited; the prompt provides no docket text, orders, complaint details, or Orange Book patent listings to support a litigation-specific summary.)